Conjugate Vaccines

By chemically linking antigens to carrier proteins, conjugate vaccines have transformed immune responses, particularly in infants and young children. This technique enhances T-cell involvement, improving immunological memory and long-term protection against encapsulated bacteria. Conjugation has enabled successful vaccines against pathogens like Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis. Research continues to optimize carrier protein selection, conjugation methods, and antigen presentation. The expanding use of synthetic linkers and bioconjugation technologies also increases stability and scalability. As antimicrobial resistance rises and new serotypes emerge, conjugate vaccines remain a cornerstone in pediatric and adult immunization programs, bridging safety and efficacy in populations with varied immune responses.

Related Sessions